Search Result

Results for "

Brincidofovir

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CMV (3) DNA/RNA Synthesis (2) Drug Metabolite (1) HSV (2) Isotope-Labeled Compounds (2) Orthopoxvirus (4)
By Research Areas:	Infection (4)
Oligonucleotides:	Phospholipids (1)

Inhibitors & Agonists

Screening Libraries

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-14532

*Brincidofovir* 5 Publications Verification CMX001; HDP-CDV	CMV HSV Orthopoxvirus	Infection
Brincidofovir (CMX001), the lipid-conjugated prodrug of Cidofovir (HY-17438), is an orally available, long-acting antiviral. Brincidofovir shows activity against a broad spectrum of DNA viruses including cytomegalovirus (CMV), adenovirus (ADV), varicella zoster virus, herpes simplex virus, polyomaviruses, papillomaviruses, poxviruses, and mixed double-stranded DNA virus infections. Brincidofovir, an oral antiviral in late stage development, has proven effective against orthopoxviruses in vitro and in vivo .

HY-14532S

Brincidofovir-d6 CMX001-d₆; HDP-CDV-d₆	Isotope-Labeled Compounds HSV CMV Orthopoxvirus	Infection
Brincidofovir-d₆ (CMX001-d₆) is the deuterium labeled Brincidofovir (HY-14532). Brincidofovir (CMX001), the lipid-conjugated prodrug of Cidofovir (HY-17438), is an orally available, long-acting antiviral. Brincidofovir shows activity against a broad spectrum of DNA viruses including cytomegalovirus (CMV), adenovirus (ADV), varicella zoster virus, herpes simplex virus, polyomaviruses, papillomaviruses, poxviruses, and mixed double-stranded DNA virus infections. Brincidofovir, an oral antiviral in late stage development, has proven effective against orthopoxviruses in vitro and in vivo. .

HY-131606S

Cidofovir diphosphate-13C3	Isotope-Labeled Compounds Orthopoxvirus Drug Metabolite CMV DNA/RNA Synthesis	Infection
Cidofovir diphosphate- ¹³C₃ is the ¹³C-labeled Cidofovir diphosphate (HY-131606). Cidofovir diphosphate is the intracellular active metabolite of Cidofovir (HY-17438) and its oral prodrug Brincidofovir (HY-14532). By inhibiting viral DNA polymerase (Ki ≈ 76.3 μM), cidofovir diphosphate is widely used in studies on double-stranded DNA virus infections, including cytomegalovirus (CMV), adenovirus (AdV), and poxviruses (such as monkeypox and molluscum contagiosum virus, MCV) .

HY-179638

Antiviral agent 74	Orthopoxvirus DNA/RNA Synthesis	Infection
Antiviral agent 74 is an antiviral agent consisting of Cidofovir (HY-17438) prodrug and lipid chain. Antiviral agent 74 can inhibit the activity of viral DNA polymerase by transforming into Cidofovir.Antiviral agent 74 demonstrates potent antiviral activity against vacciniavirus (VACV) (EC₅₀ = 0.156 μM) comparable to Brincidofovir (HY-14532). Antiviral agent 74 shows superior potency against monkeypox virus (MPXV) with an EC₅₀ vales of 0.202 μM. Antiviral agent 74 can be used for the research of virus infection .

Cat. No.	상품명

HY-L127

Anti-Orthopoxvirus Compound Library	37 compounds
Orthopoxvirus is a genus of viruses in the family Poxviridae and subfamily Chordopoxvirinae. The orthopoxvirus genus consists of 12 viruses including variola virus, vaccinia virus (VV), cowpox viruses (CV), monkeypox virus, and camelpox virus. Smallpox has been eradicated worldwide in 1980, but some other orthopoxvirus, such as monkeypox virus, are still threats to human health. There are not many drugs available for orthopoxvirus treatment. The only product currently available for treatment of complications of Orthopoxvirus infection is vaccinia immunoglobulin (VIG). In 2021, brincidofovir was approved by FDA for the treatment of smallpox and tecovirimat was approved by EMA for the treatment of monkeypox in 2022. A few active compounds including interferon and interferon inducers, and a variety of nucleosides or nucleotides have been reported to have activity against orthopoxvirus. MCE carefully prepared a unique collection of 37 compounds reported with the anti- orthopoxvirus activity which can be used for drug screening and other research about orthopoxvirus.

Anti-Orthopoxvirus Compound Library

37 compounds

Orthopoxvirus is a genus of viruses in the family Poxviridae and subfamily Chordopoxvirinae. The orthopoxvirus genus consists of 12 viruses including variola virus, vaccinia virus (VV), cowpox viruses (CV), monkeypox virus, and camelpox virus. Smallpox has been eradicated worldwide in 1980, but some other orthopoxvirus, such as monkeypox virus, are still threats to human health.

There are not many drugs available for orthopoxvirus treatment. The only product currently available for treatment of complications of Orthopoxvirus infection is vaccinia immunoglobulin (VIG). In 2021, brincidofovir was approved by FDA for the treatment of smallpox and tecovirimat was approved by EMA for the treatment of monkeypox in 2022. A few active compounds including interferon and interferon inducers, and a variety of nucleosides or nucleotides have been reported to have activity against orthopoxvirus.

MCE carefully prepared a unique collection of 37 compounds reported with the anti- orthopoxvirus activity which can be used for drug screening and other research about orthopoxvirus.

Cat. No.	상품명	Chemical Structure

HY-14532S

Brincidofovir-d6
Brincidofovir-d₆ (CMX001-d₆) is the deuterium labeled Brincidofovir (HY-14532). Brincidofovir (CMX001), the lipid-conjugated prodrug of Cidofovir (HY-17438), is an orally available, long-acting antiviral. Brincidofovir shows activity against a broad spectrum of DNA viruses including cytomegalovirus (CMV), adenovirus (ADV), varicella zoster virus, herpes simplex virus, polyomaviruses, papillomaviruses, poxviruses, and mixed double-stranded DNA virus infections. Brincidofovir, an oral antiviral in late stage development, has proven effective against orthopoxviruses in vitro and in vivo. .

Brincidofovir-d6

Brincidofovir-d₆ (CMX001-d₆) is the deuterium labeled Brincidofovir (HY-14532). Brincidofovir (CMX001), the lipid-conjugated prodrug of Cidofovir (HY-17438), is an orally available, long-acting antiviral. Brincidofovir shows activity against a broad spectrum of DNA viruses including cytomegalovirus (CMV), adenovirus (ADV), varicella zoster virus, herpes simplex virus, polyomaviruses, papillomaviruses, poxviruses, and mixed double-stranded DNA virus infections. Brincidofovir, an oral antiviral in late stage development, has proven effective against orthopoxviruses in vitro and in vivo. .

HY-131606S

Cidofovir diphosphate-13C3
Cidofovir diphosphate- ¹³C₃ is the ¹³C-labeled Cidofovir diphosphate (HY-131606). Cidofovir diphosphate is the intracellular active metabolite of Cidofovir (HY-17438) and its oral prodrug Brincidofovir (HY-14532). By inhibiting viral DNA polymerase (Ki ≈ 76.3 μM), cidofovir diphosphate is widely used in studies on double-stranded DNA virus infections, including cytomegalovirus (CMV), adenovirus (AdV), and poxviruses (such as monkeypox and molluscum contagiosum virus, MCV) .

Cidofovir diphosphate-13C3

Cidofovir diphosphate- ¹³C₃ is the ¹³C-labeled Cidofovir diphosphate (HY-131606). Cidofovir diphosphate is the intracellular active metabolite of Cidofovir (HY-17438) and its oral prodrug Brincidofovir (HY-14532). By inhibiting viral DNA polymerase (Ki ≈ 76.3 μM), cidofovir diphosphate is widely used in studies on double-stranded DNA virus infections, including cytomegalovirus (CMV), adenovirus (AdV), and poxviruses (such as monkeypox and molluscum contagiosum virus, MCV) .

Cat. No.	상품명		Classification

HY-14532

*Brincidofovir* 5 Publications Verification CMX001; HDP-CDV		Phospholipids
Brincidofovir (CMX001), the lipid-conjugated prodrug of Cidofovir (HY-17438), is an orally available, long-acting antiviral. Brincidofovir shows activity against a broad spectrum of DNA viruses including cytomegalovirus (CMV), adenovirus (ADV), varicella zoster virus, herpes simplex virus, polyomaviruses, papillomaviruses, poxviruses, and mixed double-stranded DNA virus infections. Brincidofovir, an oral antiviral in late stage development, has proven effective against orthopoxviruses in vitro and in vivo .

온라인 문의

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
호칭			Country or Region *
고객명 *			회사명 *
Department *
메일주소 *			상품명 *
Cat. No.			Requested quantity *
전화번호 *
비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
이메일 *

	Sorry, but the email address you supplied was invalid.